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Abstract
Introduction The mainstay of management for locally
advanced rectal cancer is chemoradiotherapy followed
by surgical resection. Following chemoradiotherapy, a
complete response may be detected clinically and radio-
logically (cCR) prior to surgery or pathologically after
surgery (pCR). We aim to report the overall complete
pathological response (pCR) rate and the reliability of
detecting a cCR by conventional pre-operative imaging.
Methods A pre-planned analysis of the European Society
of Coloproctology (ESCP) 2017 audit was performed.
Patients treated by elective rectal resection were included.
A pCR was defined as a ypT0 N0 EMVI negative primary
tumour; a partial response represented any regression
from baseline staging following chemoradiotherapy. The
primary endpoint was the pCR rate. The secondary end-
point was agreement between post-treatment MRI
restaging (yMRI) and final pathological staging.
Results Of 2572 patients undergoing rectal cancer sur-
gery in 277 participating centres across 44 countries,
673 (26.2%) underwent chemoradiotherapy and sur-
gery. The pCR rate was 10.3% (67/649), with a partial
response in 35.9% (233/649) patients. Comparison of
AJCC stage determined by post-treatment yMRI with
final pathology showed understaging in 13% (55/429)
and overstaging in 34% (148/429). Agreement between
yMRI and final pathology for T-stage, N-stage, or
AJCC status were each graded as ‘fair’ only (n = 429,
Kappa 0.25, 0.26 and 0.35 respectively).
Conclusion The reported pCR rate of 10% highlights
the potential for non-operative management in selected
cases. The limited strength of agreement between basic
conventional post-chemoradiotherapy imaging assess-
ment techniques and pathology suggest alternative
markers of response should be considered, in the con-
text of controlled clinical trials.
Keywords Rectal surgery, rectal cancer, pathology,
radiology, neoadjuvant therapy, surgical oncology,
deferral of surgery
What does this paper add to the literature?
This paper highlights the potential for selective non-
operative management of rectal cancer with long-course
chemoradiotherapy. We report a complete pathological
response rate of 10.3% in an international audit. There
was limited agreement between basic conventional post-
chemoradiotherapy imaging and pathological staging,
demonstrating a need for better use of current markers
or more sensitive markers of treatment response.
Introduction
Approximately 450 000 rectal cancers are diagnosed
worldwide annually [1]. In developed countries, in
which 55% of these diagnoses are made, 45–55% of
electively managed patients will receive chemoradiother-
apy prior to the cancer resection [2]. The surgical resec-
tion, performed according to the principles of total
mesorectal excision (TME), is widely regarded as the
mainstay of curative treatment for resectable rectal can-
cer [3]. However, rectal cancer resections have signifi-
cant morbidity along with a 90-day mortality of
approximately 4–5% [2,4]. Furthermore, the long-term
consequences of treatment of pre-operative radiotherapy
and surgery can profoundly impair quality of life, this
may be attributed to bowel dysfunction following a
restorative procedure [5,6], living with the challenges
and complications of a permanent stoma [7], or geni-
tourinary side effects of treatment [8].
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Over the past decade there has been increasing inter-
est in avoiding the consequences of a TME procedure
through organ preserving approaches [9,10]. This is on
the proviso that equivalent or favourable oncological
outcomes can be achieved with a lower overall morbid-
ity. One approach has been to consider deferral of sur-
gery, whereby patients who have responded favourably
to pre-operative chemoradiotherapy do not undergo
surgery if there is no evidence of detectable tumour by
clinical, endoscopic and radiological surveillance. These
patients are diagnosed with a clinical complete response
(cCR), this approach is also termed “Watch and Wait”
or ‘Non-Operative Management’ [11,12].
The original Watch and Wait concept was based on
the observation of no residual tumour cells (a pathologi-
cal complete response (pCR)) in up to 26.8% of rectal
cancer specimens following chemoradiotherapy [10]. Fur-
thermore, with optimal follow-up, selected patients who
participate in these programmes were reported to have
favourable oncological outcomes compared with patients
who underwent surgery, with 5-year disease-free and
overall survival exceeding 90% [10]. Deferral of surgery is
increasingly reported as a feasible approach for rectal can-
cer management, with acceptable detection rates of
regrowth and safe surgical salvage [13,14]. A meta-analy-
sis of 17 studies, from centres with established surveil-
lance protocols for deferral of surgery, reported a clinical
complete response rate (cCR) of 22.4% (95% CI:14.3–
31.8) [15]. However most of these centres pursue strate-
gies thought to enhance the likelihood of a favourable
response, including consolidation or induction
chemotherapy sensitizing regimes [16] radiotherapy dose
escalation of up to 66 Gy [17] and offering chemoradio-
therapy to smaller tumours (over 25% of the tumours in
the meta-analysis were cT2 or less) [15].
The aim of this study was to record the complete
pathological response rate reported in a ‘real world’ set-
ting in order to determine the potential for widespread
uptake of non-operative rectal cancer management. We
also aimed to determine whether conventional radiolog-
ical assessment of response to chemoradiotherapy is suf-
ficiently reliable to feasibly consider generalised
implementation of non-operative management in cur-
rent clinical practice.
Methods
Protocol
This prospective, observational, multi-centre study was
conducted in line with a pre-specified protocol (http://
www.escp.eu.com/research/cohort-studies). An exter-
nal pilot of the protocol and data capture system was
conducted in five international centres prior to launch,
allowing refinement of the study tool and delivery.
This data was not included within the main study
analysis.
Centre eligibility
Any unit performing gastrointestinal surgery was eligible
to register to enter patients into the study. No mini-
mum case volume, or centre-specific limitations were
applied. The study protocol was disseminated to regis-
tered members European Society of Coloproctology
(ESCP), and through national surgical or colorectal
societies. Units recruiting patients to rectal cancer trials
were still eligible to participate in the study.
Patient eligibility
Adult patients (≥ 16 years) undergoing elective
resection for rectal cancer treated with long-course
pre-operative chemoradiotherapy, with or without meta-
static disease, were extracted from the main audit data-
base. A rectal cancer was defined as an adenocarcinoma
0–15 cm from the anal verge on rigid sigmoidoscopy or
MRI. Concomitant chemoradiotherapy was a manda-
tory inclusion criteria, however the dose of chemother-
apy and the delivery of long-course radiotherapy was
administered to according to unit and clinician prefer-
ence. Patients undergoing palliative pre-operative ther-
apy, chemotherapy alone or short course radiotherapy
were excluded.
Data capture
Consecutive sampling was performed for eligible
patients over an 8-week study period in each included
centre. Local investigators commenced data collection
on any date between the 1 February 2017 and 15
March 2017, with the last eligible patient being
enrolled on 10 May 2017. Small teams of up to five
surgeons or surgical trainees worked together to collect
prospective data on all eligible patients at each centre.
Quality assurance was provided by at least one consul-
tant or attending-level surgeon. Data was recorded con-
temporaneously and stored on a secure, user-encrypted
online platform (REDCap) without using patient identi-
fiable information. Centres were asked to validate that
all eligible patients during the study period had been
entered, and to attain > 95% completeness of data field
entry prior to final submission.
Demographic data including Age, Gender, American
Society of Anaesthesiologists (ASA) classification grade,
smoking history, body mass index, cardiovascular
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disease, indication for surgery and disease location. The
index operation, operative steps, approach, duration and
morbidity were recorded. Tumour staging information
(T-stage, N-stage, extramural vascular invasion),
recorded at three different timepoints, were available: 1.
Baseline pre-neoadjuvant treatment MRI staging; 2.
Post-treatment MRI staging; 3. Post-treatment patho-
logical staging. Staging was summarised according to
IUCC/AJCC TNM 7 system [18]. The MRI Rectum
was performed according to individual unit protocol.
An MRI for baseline staging was mandatory for all rec-
tal cancers included in the study, the post treatment
MRI was encouraged but was not compulsory. A com-
plete pathological response (pCR) has been defined pre-
viously as ypT0,N0 [19], our definition also required
the ypEMVI status to be negative. Tumor regression
was staged into three categories: a complete pathologi-
cal response (no visible cancer cells), a partial response
(regression from baseline MRI to pathology for one or
more of T stage, N stage, EMVI status), and no
change/progression from the baseline MRI staging.
The circumferential rectal margin (CRM) was regarded
as involved if the microscopic tumor extension reached
≤ 1 mm from the margin. Central quality control of
surgical specimens by pathologic examination was not
performed.
Outcome measures
The primary outcome measure was the rate of complete
pathological response. The secondary outcome measure
was the concordance of the TNM-based post-treatment
MRI assessment and post-treatment pathological stag-
ing for T stage, N stage and overall AJCC TNM grade,
assessed using Kappa agreement and the Intraclass Cor-
relation Coefficient.
Statistical analysis
This report has been prepared in accordance to guideli-
nes set by the STROBE (strengthening the reporting of
observational studies in epidemiology) statement for
observational studies [20]. Patient, disease and operative
characteristics were compared using descriptive analysis
and tests of normality were used to guide analysis.
Chi-squared test was used for categorical data, Stu-
dent’s t-test for normally distributed continuous data
and Mann-Whitney U test for non-parametric data. To
explore associations between T-stage, nodal status,
EMVI status and tumour height with pathological com-
plete response univariable logistic regression models
were fitted, described as odds ratios with 95% confi-
dence intervals.
The reliability of post-treatment MRI restaging to
assess response to neoadjuvant therapy was assessed by
the Kappa agreement between the post-treatment MRI
and pathology T-, N- and AJCC-staging [21]. A Kappa
value of < 0.20 was interpreted as ‘Poor’, 0.21–0.40 as
‘Fair’, 0.41–0.60 as ‘Moderate’, 0.61–0.80 as ‘Good’,
and 0.81–1.00 as ‘Very good’. An estimate of the Intra-
class Correlation Coefficient was also reported, with
95% exact confidence intervals (95% CI) derived using
the variance components from a one-way ANOVA
[22,23]. Data analysis was undertaken using R Studio
V3.1.1 (R Foundation, Boston, MA, USA).
Ethical approval
All participating centres were responsible for compliance
to local approval requirements for ethics approval or
indemnity as required. In the UK, the National Research
Ethics Service tool recommended that this project was
not classified as research, and the protocol was registered
as clinical audit in all participating centres.
Results
Figure 1 shows inclusion of patients within this study.
A total of 2572 patients underwent surgery for rectal
cancer in 277 participating centres across 44 countries.
Of these, 673 (26.2%) underwent CRT and TME sur-
gery. Twenty four patients were excluded due to miss-
ing MRI or pathology staging. The median (IQR) age
of the remaining 649 patients was 65 years (56–
71 years). 35% (229/649) were female.
pCR was reported in 10.3% (67/649) patients. An
overall partial response occurred in 35.9% (233/649),
with T stage regression in 42.8% (278/649), N stage
regression in 71.6% of those with baseline node positiv-
ity (111/155), and EMVI regression in 82.5% with
baseline mrEMVI positivity (33/40). No regression
occurred in 53.8% (349/649) patients. Treatment fail-
ure with progression of T-staging was seen in 9.4%
(53/562), N-staging in 8.9% (52/583) and EMVI-sta-
tus in 17.6% (99/561).
Demographic and operative data are compared
according to tumour response in Table 1. Overall the
mean (SD) tumour height was 4.1 cm [1.9], whereas
the pCR group were significantly closer to the anal
verge (mean (SD) 3.2 cm [1.7], P < 0.007). Patients
with a pCR were more likely to undergo a restorative
resection 73.1% (P = 0.004) and a significantly higher
proportion of robotic cases were performed on patients
with a pCR (27%[13/48], P < 0.001) compared with
11.4% [38/333] and 6.0% [16/268] for laparoscopic
and open approaches, respectively. Response was not
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influenced by age, gender and patient fitness in this ser-
ies. The degree of regression did not influence Clavien
Dindo reported complication rates.
Baseline MRI staging (n = 649), post-CRT MRI
staging (n = 429), and pathological staging are com-
pared against tumour response in Table 2. A post-treat-
ment MRI was performed in 66.1% (429/649) of
patients. According to the baseline MRI over 70% of
tumours were T3 in all response groups, only 4.5%
of pCR tumours were mrT4 and the highest proportion
of T4 tumours were in the partial response group
23.6% (55/233). mrT1 were reported in 8 (1.2%) cases,
these were mrEMVI or mrN2 +ve tumours and all
patients were non-responders. Following CRT, ymrT1
was reported in 7.7% overall and in 20% of pCR group.
Figure 2 displays response rates by tumour height and
pre-treatment MRI T-stage. Complete response was
more common in T1/T2 tumours than T3/T4
Records uploaded to the ESCP 
REDCap database (n=5788) 
Excluded from analysis (n=147)
•  Patients <16 years (n=2)
•  Missing anastomosis type (n=49)
•  Missing anastomotic leak outcome (n= 65)
•  Missing complication outcome (n=31)
Patients undergoing rectal surgery (n=3079) 
Patients undergoing elective surgery (n=4487)
Excluded from analysis (n=1408) 
♦  Patient undergoing resection involving the colon 
only (n=1398) 
♦  Missing (n=10) 
Excluded from analysis (n=1154) 
♦  Emergency surgery (less than 24h) (n=591) 
♦  Expedited surgery (less than 2 weeks) (n=563) 
Eligible and completed records (n=5641) 
Enrollment 
Data cleaning
Cohort selection 
Elective rectal cancer resection with long course CRT (n=649) 
•  Pathological Complete Response (pCR) (n=67) – 10.3%
•  Partial Response (n=233)   
•  No response (n=349) 
Excluded from analysis (n=1893) 
♦  No chemoradiotherapy (n=1611) 
♦  Short course radiotherapy (n = 177)
♦  Palliative chemotherapy (n=86)
♦  Missing adjuvant therapy data (n=28) 
♦  Missing response data (n=30)Included in analysisNeoadjuvant 
therapy
Patients undergoing cancer surgery (n=2579) 
Excluded from analysis (n=507) 
♦  Benign disease (n=500)
Figure 1 Flowchart for patients included in the analysis of pre-operative chemoradiotherapy followed by elective rectal cancer
surgery.
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tumours (14.5% vs 9.7%), although this association was
non-significant (T3/T4; OR: 0.64, 0.34–1.30,
P = 0.19). Despite trends towards a higher pCR rate in
low or middle rectal disease, neither tumour height
(Low rectum; OR: 1.82, 0.765.43, P = 0.22, Middle
rectum; OR: 1.64, 0.655.02, P = 0.33) or EMVI sta-
tus (EMVI positive; OR: 1.26, 0.42–3.07, P = 0.64)
were significantly associated with complete response.
Node positivity at baseline was significantly associated
with a lower rate of pCR (OR: 0.40, 0.17–0.81,
P = 0.02).
The pathology data is also summarised in Table 2.
There was no tumour in the pCR group and therefore
the grade of differentiation could not be determined,
however there was no difference in the tumour grade for
partial and non-responders. Non-responders were signifi-
cantly more likely than partial responders to be ypEMVI
positive (12.9% [30/233] vs 24.4% [85/349],
P < 0.001). The overall pCRM rate was 6.2% [40/649].
The post-CRT MRI staging (n = 429) is compared
with pathology staging in Table 3. Overall understaging
occurred in 14% (61/429) and 12.8% (55/429) of ypT
Table 1 Characteristics of patients undergoing long course neoadjuvant chemoradiotherapy.
Factor Level Total %
Pathological assessment of response to CRT
Complete (%) Partial (%) None (%) P-value
649 100.0 67 (10.3) 233 (35.9) 349 (53.8)
Patient and disease factors
Age < 55 131 20.2 12 (17.9) 44 (18.9) 75 (21.5) 0.61
55–70 308 47.5 29 (43.3) 120 (51.5) 159 (45.6)
70–80 182 28.0 24 (35.8) 60 (25.8) 98 (28.1)
> 80 28 4.3 2 (3.0) 9 (3.9) 17 (4.9)
Gender Female 229 35.3 24 (35.8) 88 (37.8) 117 (33.5) 0.57
Male 420 64.7 43 (64.2) 145 (62.2) 232 (66.5)
ASA class Low risk (ASA 1–2) 464 71.5 48 (71.6) 171 (73.4) 245 (70.2) 0.16
High risk (ASA 3–5) 178 27.4 17 (25.4) 58 (24.9) 103 (29.5)
Missing 7 1.1 2 (3.0) 4 (1.7) 1 (0.3)
BMI Normal weight 237 36.5 21 (31.3) 87 (37.3) 129 (37.0) 0.67
Underweight 16 2.5 0 (0.0) 7 (3.0) 9 (2.6)
Overweight 243 37.4 28 (41.8) 85 (36.5) 130 (37.2)
Obese 143 22.0 16 (23.9) 49 (21.0) 78 (22.3)
Missing 10 1.5 2 (3.0) 5 (2.1) 3 (0.9)
Tumour height
(measured from
anal margin) (cm)
High rectum 77 11.9 5 (7.5) 24 (10.3) 48 (13.8) 0.37
Middle rectum 225 34.7 23 (34.3) 77 (33.0) 125 (35.8)
Low rectum 347 53.5 39 (58.2) 132 (56.7) 176 (50.4)
Tumour height (cm) Mean (SD) 3.2 (1.7) 3.7 (2.1) 4.5 (3.5) 0.007
Operation factors
Operative approach Open 268 41.3 16 (23.9) 96 (41.2) 156 (44.7) < 0.001
Laparoscopic 333 51.3 38 (56.7) 127 (54.5) 168 (48.1)
Robotic 48 7.4 13 (19.4) 10 (4.3) 25 (7.2)
Duration (minutes) Mean (SD) 262.8 (97.5) 243.7 (95.8) 246.3 (97.2) 0.24
Approach Anterior Resection 424 65.3 49 (73.1) 154 (66.1) 221 (63.3) 0.04
Hartmanns 37 5.7 5 (7.5) 5 (2.1) 27 (7.7)
APE 121 18.6 7 (10.4) 45 (19.3) 69 (19.8)
ELAPE 67 10.3 6 (9.0) 29 (12.4) 32 (9.2)
Defunctioning stoma Yes 345 53.2 42 (62.7) 129 (55.4) 174 (49.9) 0.11
No 304 46.8 25 (37.3) 104 (44.6) 175 (50.1)
Outcomes
Complication grade None 364 56.1 38 (56.7) 135 (57.9) 191 (54.7) 0.75
Grade 1–2 190 29.3 18 (26.9) 67 (28.8) 105 (30.1)
Grade 3–5 92 14.2 11 (16.4) 31 (13.3) 50 (14.3)
Missing 3 0.5 0 (0.0) 0 (0.0) 3 (0.9)
CRT, chemoradiotherapy. Pathological assessment of response to CRT: complete response (ypT0,N0, EMVI-ve). Partial response
(regression from baseline MRI T stage), none (no change or progression from baseline MRI T stage).
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Table 2 Magnetic resonance imaging and pathological staging of included patients.
Factor Level Total %
Pathological Assessment of Response to CRT
Complete (%) Partial (%) None (%) P-value
649 100.0 67 (10.3) 233 (35.9) 349 (53.8)
Pre-treatment MRI staging
mrT T1 8 1.2 0 (0.0) 0 (0.0) 8 (2.3) < 0.001
T2 75 11.6 12 (17.9) 11 (4.7) 52 (14.9)
T3 479 73.8 52 (77.6) 167 (71.7) 260 (74.5)
T4 87 13.4 3 (4.5) 55 (23.6) 29 (8.3)
mrN N0 497 76.6 59 (88.1) 141 (60.5) 294 (84.2) < 0.001
N1 89 13.7 3 (4.5) 55 (23.6) 31 (8.9)
N2 66 10.2 5 (7.5) 37 (15.9) 24 (6.9)
mrEMVI No 561 86.4 58 (86.6) 194 (83.3) 309 (88.5) 0.389
Yes 40 6.2 5 (7.5) 16 (6.9) 19 (5.4)
Missing 48 7.4 4 (6.0) 23 (9.9) 21 (6.0)
mrAJCC Stage 1 58 8.9 10 (14.9) 0 (0.0) 48 (13.8) < 0.001
Stage 2 408 62.9 43 (64.2) 119 (51.1) 246 (70.5)
Stage 3 121 18.6 7 (10.4) 65 (27.9) 49 (14.0)
Stage 4 62 9.6 7 (10.4) 49 (21.0) 6 (1.7)
Post-treatment MRI re-staging
Post treatment MRI performed Yes 429 66.1 39 (58.2) 164 (70.4) 226 (64.8) 2.12
No 220 33.9 28 (41.8) 69 (29.6) 123 (35.2)
Of those restaged (n = 429) T0/1 33 7.7 8 (20.5) 13 (7.9) 12 (5.3) < 0.001
ymrT T2 107 24.9 14 (35.9) 37 (22.6) 56 (24.8)
T3 226 52.7 14 (35.9) 78 (47.6) 134 (59.3)
T4 63 14.7 3 (7.7) 36 (22.0) 24 (10.6)
ymrN N0 229 53.4 27 (69.2) 102 (62.2) 100 (44.2) < 0.001
N1 141 32.9 11 (28.2) 40 (24.4) 90 (39.8)
N2 59 13.8 1 (2.6) 22 (13.4) 36 (15.9)
ymrEMVI No 346 80.7 35 (89.7) 133 (81.1) 178 (78.8) 0.376
Yes 67 15.6 3 (7.7) 23 (14.0) 41 (18.1)
Missing 14 3.3 1 (2.6) 7 (4.3) 6 (2.7)
ymr AJCC stage Stage 1 99 23.1 16 (41.0) 41 (25.0) 42 (18.6) < 0.001
Stage 2 115 26.8 11 (28.2) 59 (36.0) 45 (19.9)
Stage 3 170 39.6 12 (30.8) 61 (37.2) 97 (42.9)
Stage 4 44 10.3 0 (0.0) 2 (1.2) 42 (18.6)
Missing 1 0.2 0 (0.0) 1 (0.6) 0 (0.0)
Post-operative pathological staging
ypT stage T0 77 11.9 67 (100.0) 2 (0.9) 8 (2.3) < 0.001
T1 34 5.2 0 (0.0) 28 (12.0) 6 (1.7)
T2 181 27.9 0 (0.0) 121 (51.9) 60 (17.2)
T3 310 47.8 0 (0.0) 67 (28.8) 243 (69.6)
T4 47 7.2 0 (0.0) 15 (6.4) 32 (9.2)
ypN stage N0 431 66.4 67 (100.0) 212 (91.0) 152 (43.6) < 0.001
N1 150 23.1 0 (0.0) 15 (6.4) 135 (38.7)
N2 68 10.5 0 (0.0) 6 (2.6) 62 (17.8)
ypEMVI No 534 82.3 67 (100.0) 203 (87.1) 264 (75.6) < 0.001
Yes 115 17.7 0 (0.0) 30 (12.9) 85 (24.4)
Differentiation grade Poor 72 11.1 – 27 (11.6) 45 (12.9) < 0.001
Moderate 337 51.9 – 128 (54.9) 209 (59.9)
Well 161 24.8 – 75 (32.2)86 (24.6)
Missing 79 12.2 67 3 9
Prefix notations: mr, MRI staging; p, pathology staging; y, staging following chemoradiotherapy (CRT). ymr, MRI staging follow-
ing CRT; AJCC, American Joint Committee on Cancer; EMVI, extramural vascular invasion; N, node; T, tumour.
Colorectal Disease ª 2018 The Association of Coloproctology of Great Britain and Ireland. 20 (Suppl. 6), 58–68 63
The 2017 European Society of Coloproctology (ESCP) collaborating group Safe deferral of rectal cancer surgery
stage and ypAJCC grade cancers respectively. Overstag-
ing was reported in 35% (151/429) of ypT staging and
34% (148/429) of ypAJCC grading. Table 4 shows that
the agreement between the post-treatment MRI and
Pathology was graded ‘fair’ for T stage, N stage and
AJCC status (Kappa 0.25, 0.26 and 0.35 respectively).
Figure 2 Differences in treatment response by tumour height.
Table 3 Comparison of post-treatment MRI and pathological staging. A post-treatment MRI was performed in 66.1% (429/649)
cases. Under-staging (blue) indicated lower staging by post-treatment MRI than by pathology. Overstaging (yellow) indicated
higher staging by post-treatment MRI than by pathology.
MRI tumor classification pT0/1 pT2 pT3 pT4 Total (n) Over staged, % Under staged, % Accuracy, %
Pathologic tumor classification – yT stage
rT0/T1 14 5 6 0 25 - 44 56
rT2 21 44 30 1 96 22 32 46
rT3 14 57 129 14 214 33 7 60
rT4 3 8 31 16 58 72 – 28
Total (n) 52 114 196 31 393 34 14 52
MRI tumor classification pN0 pN1 pN2 Total (n) Over staged, % Under staged, % Accuracy, %
Pathologic tumor classification – yN stage
rN0 167 32 8 207 – 19 81
rN1 65 46 22 133 49 16 35
rN2 21 15 17 53 68 – 32
Total (n) 253 93 47 393 26 16 58
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Discussion
This large, prospective international audit identified a
pCR rate of 10.3% for patients with rectal cancer trea-
ted with preoperative chemoradiotherapy. This data was
simultaneously collected from 262 units over a period
of six weeks. It provides a unique and truly generalised
‘snapshot’ of the pathological response rate in current
practice. Many regard a pathological response as a
mixed blessing; on the one hand this reflects a favour-
able prognosis but on the other it may indicate an
unnecessary operation with the sequelae that can follow.
Consequently, there is increasing interest in trying to
identify a complete response after chemoradiotherapy
on clinical and radiological (cCR) grounds rather than
by pathological assessment (pCR). However, this ‘real-
world’ MRI staging data gives us an indication that if
current basic staging tools are used in isolation, they
will be inadequate for accurately identifying and safely
monitoring ‘deferral of surgery’ patients.
The pCR rate reported in this study is consistent
with outcomes reported in large trials that used single
agent concomitant chemotherapy and a radiotherapy
dose of at least 45 Gy. The FFCD 9203, EORTC
22921 and the German Rectal Cancer Study (CAO/
ARO/AIO-94) trials have been described extensively
elsewhere [24–26]. In summary these trials recruited
cT3 or resectable cT4M0 adenocarcinoma of the rec-
tum, located within 15, 15 and 16 cm from the anal
verge respectively [24–26]. These trials reported pCR
rates with pre-operative CRT of 11.4%, 14% and 8%
respectively [24–26]. One review of phase II and III
studies identified pCR rates ranging from 0–67% with
an overall pCR rate of 13.5% [27].
This current study identified that a pCR was associ-
ated with a lower tumour height. This finding has been
reported previously and authors postulate that lower
tumours are fixed by the pelvic floor muscles allowing
radiotherapy to be delivered more consistently which
allows for a favourable response rate [28]. A significantly
higher proportion of patients in the pCR group had a
node negative tumour at baseline. As authors have
previously discussed, this may indicate that earlier stage
tumours are more likely to produce a complete clinical
response or this may reflect a more biologically indolent
tumour that is more likely to respond favourably to
treatment [15,28,29]. The size of the tumour may also
influence complete response rates [29], however in this
study tumours were predominately mrT3 and the MRI
baseline staging suggested CRT was given in order to
downstage locally advanced tumours rather than to
achieve a complete response in early stage tumours.
Other factors previously shown to be associated with
an increased response rate include dual concomitant
chemotherapy [27], induction chemotherapy [30], con-
solidation chemotherapy [31,32], allowing time for
regression between CRT and surgery [33], and intensi-
fied pre-operative radiotherapy [17]. The pathological
assessment can also influence the pCR rate. The more
thorough the histopathology technician and the pathol-
ogist, the less likely they are to find a pCR. However
recent guidelines for assessing post-CRT rectal cancer
specimens provide recommendations on the number of
levels that should be cut from each tumour block.
These recommendations are likely to standardise the
pathological assessment of response [34].
When the response to CRT is favourable and a pCR
is achieved it can be regarded as an encouraging out-
come. Many patients with a pCR will be reassured by
the absence of a cancer. Furthermore, the longterm
outcomes are highly favourable; the German Rectal
Cancer trial reported a 10 year DFS of 89.5% with a
pCR, compared with 63% when minimal tumour regres-
sion occurred (p = 0.008) [35]. On the other hand this
represents a missed opportunity for organ preservation.
In selected patients it is possible to avoid surgery. Thus
much of the morbidity may be prevented along with
the reported 90-day post-operative mortality of 4–5%
[4]. Deferral of surgery has now been reported for 867
patients from 23 studies [13]. In highly selected cases,
motivated centres with established surveillance protocols
report no significant difference between ‘deferral of sur-
gery’ for a cCR compared with surgery for a pCR [13].
They found no difference in non-regrowth recurrence
Table 4 Agreement between post-treatment MRI and pathological staging.
Pathological stage
ymr v pathology
Agreement (%) Agreement (Kappa) Kappa P-value Intraclass correlation coefficient
ypT-stage 50.7 0.249 < 0.001 0.26 (0.09–0.84)
ypN-stage 58.8 0.264 < 0.001 0.25 (0.08–0.93)
ypAJCC stage 52.8 0.348 < 0.001 0.35 (0.14–0.88)
Agreement refers to the concordance of post-treatment MRI re-staging with pathological staging.
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(RR 0.58, 95% CI 0.18–1.90), disease-free survival (HR
0.56, 95% CI 0.20–1.60), or overall survival (HR 3.91,
95% CI 0.57–26.72) [13].
The challenge that currently prevents widespread
uptake of ‘deferral of surgery’ is the inability to reliably
identify and monitor responders. In our study ‘fair’
Kappa agreements of 0.25, 0.26 and 0.35 were reported
for ypT stage, ypN stage and ypAJCC grade respectively
with understaging occurred in over 10% of cases and
overstaging in over 30% of cases. These Kappa agree-
ments exceed published agreements for other methods of
assessing response such as mrRECIST [Response Evalua-
tion Criteria In Solid Tumors] criteria and MR volumetric
analysis (Kappa 0.12 and 0.36 respectively) [36]. How-
ever higher Kappa agreement scores of > 0.4 have been
reported for ymr versus pT stage assessment in selected
centres [36]. Nevertheless, these data suggests that the
techniques used in a typical international surgical unit for
post-treatment MRI staging are insufficiently reliable to
allow for the safe delivery of deferral of surgery.
In selected centres, multidisciplinary team (MDT) ori-
entated standardised protocols have contributed to sig-
nificant improvements in the interpretation of response
to chemoradiotherapy; multimodal assessment, with T2
weighted-MRI serving as the primary screening tool, in
conjunction with clinical and endoscopic examination, is
used to evaluate response [37–39]. This suggests that
with optimal training and experience, current tools can
be used effectively to select patients whose tumours have
responded favourably to chemoradiotherapy. Neverthe-
less in a global setting we share the view of the authors of
the MERRION study [40] and Putte et al. who sug-
gested current imaging modalities have a low accuracy for
predicting a true pathological complete response, indicat-
ing that deferral of surgery should not be offered outside
of well-designed clincal trials [41]. Whilst we need to
search for alternative methods for assessing response.
The actively recruiting TRIGGER randomised con-
trol trial is testing methods to identify, and safely moni-
tor, clinical complete responders [42]. The trial, uses
current MRI imaging in a smarter way, to identify clini-
cal complete responders by applying a 5-point MRI
tumour regression grade (mrTRG), which most closely
resembles the Mandard pathologic TRG system [39].
The basic principle of both grading systems relate to
the ratio of tumour to fibrosis following CRT. This is
the first imaging technique that has been shown to
assess the degree of tumour regression and to correlate
the findings with pathology and with long-term survival
[37,43]. A unique aspect of this trial is that participat-
ing units are trained to report mrTRG and may only
take part when the unit radiologist completes a training
dataset for mrTRG and achieves a high degree of
agreement with the index radiologist (Kappa ≥ 0.7)
[42]. TRIGGER may enable the dissemination of a
standardised, reliable, evidence based technique for
assessing post-chemoradiotherapy response.
There are a number of limitations with this study.
There is a lack of detail in terms of treatment approach.
We did not know the exact radiotherapy dose used,
whether pre-operative ‘consolidation’ or ‘induction’ sys-
temic chemotherapy was used in addition to CRT or
the standard waiting time between completion of CRT
(or short course radiotherapy) and surgery. Conse-
quently we have not been able to perform a multivariate
analysis to explore the key risk factors for predicting a
favourable response to CRT. Although it was compul-
sory for data to be reviewed by a senior member of the
department prior to submission, no external audit of
the radiology or pathology was performed and we could
not be certain that recogised standardised methods were
performed [34,42]. For the purposes of this study we
believe this to be acceptable because it simply reflects
the ‘real-world’ data that we aimed to assess. Finally,
only patients undergoing surgery were included in the
study. It is possible that a number of units already prac-
tice deferral of surgery. However, for the reasons out-
lined above we would recommend that this is
performed within the context of a clinical trial.
Conclusions
The pathological complete response (pCR) rate of 10%
reported in this international audit is consistent with rates
reported in clinical trials that used concomitant chemora-
diotherapy. This highlights the potential for non-opera-
tive management in selected rectal cancer patients,
however the number of eligible patients may be increased
if treatment strategies that enhance the overall response
rate are pursued. The second barrier to non-operative
management is the limited strength of agreement
between post-CRT imaging and pathology. This suggests
that assessing response with crude measures such as post-
treatment T stage and post-treatment AJCC grade are
not reliable or generalisable. Alternative detection meth-
ods, such as mrTRG with serial assessment, need to be
considered in the context of clinical trials in order to fea-
sibly allow safe widespread uptake of deferral of surgery.
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